Hang Zhang

Dr. Hang Zhang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Experimental Cell Research
Verified
Journal Article
Closed access
YWYu Wande
Yu Wande
LJLuo Jie
Luo Jie
ZAZhang Aikai
Zhang Aikai
ZYZheng Yaguo
Zheng Yaguo
ZLZhu Linlin
Zhu Linlin
HZHang Zhang
Hang Zhang

1 April 2019 in Pulmonary Circulation
Verified
Journal Article
Open access
HZHang Zhang
Hang Zhang
WYWande Yu
Wande Yu
JZJuan Zhang
Juan Zhang
DXDujiang Xie
Dujiang Xie
YGYue Gu
Yue Gu
SCShao-Liang Chen
Shao-Liang Chen
This study aimed to determine the benefits and correlated mechanisms of pulmonary artery denervation (PADN) for heart failure (HF) pulmonary hypertension (PH). PH secondary to HF is associated with poor clinical outcomes because there is no proper therapy for it. PADN showed improved outcomes for patients with HF‐PH. However, the underlying mechanisms remain unknown. Supracoronary aortic banding (SAB) was used to create HF‐PH models. Sprague‐Dawley rats were randomly assigned to control, SAB, sham, SAB with PADN, and SAB without PADN groups. Surgical (longitudinally damaging vessel nerves) and chemical (10% phenol applied to the surface of nerves) PADN was performed for animals in the SAB with PADN group. Morphological, echocardiographic, hemodynamic, and protein expression changes were measured four weeks thereafter. Adrenergic receptor (AR) expressions of pulmonary arteries from four HF‐PH patients and four patients without PH were measured. Ten HF‐PH patients who underwent PADN were followed‐up for six months. SAB‐induced HF‐PH was achieved by 50% of animals. Surgical and chemical PADN was associated with significant improvements in pulmonary artery muscularization, hemodynamics, and right ventricular functions. In pulmonary arterial specimens from HF‐PH patients, β2‐AR and α1A/B‐AR, as well as eNOS, were downregulated and α1D‐AR was upregulated compared to those from patients without PH. PADN led to a mean increase of 84 m during the 6‐min walk distance for HF‐PH patients at six‐month follow‐up. HF‐PH was characterized by downregulated β2‐AR, α1A‐AR, and α1B‐AR and by upregulated α1D‐AR. PADN is associated with significant improvements in hemodynamics and pulmonary artery remodeling.

27 July 2020 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
AZAikai Zhang
Aikai Zhang
FYFenfang Yu
Fenfang Yu
WYWande Yu
Wande Yu
PYPeng Ye
Peng Ye
PLPengfei Liu
Pengfei Liu
HZHang Zhang
Hang Zhang

21 August 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
WYWande Yu
Wande Yu
YGYue Gu
Yue Gu
PCPeiP Chen
PeiP Chen
LJLuo Jie
Luo Jie
PLPengfei Liu
Pengfei Liu
HZHang Zhang
Hang Zhang

20 September 2016 in Chinese Medical Journal
Verified
Journal Article
Open access
PDF file
HZHang Zhang
Hang Zhang
CPChang Pan
Chang Pan
JZJuan Zhang
Juan Zhang
LZLin-Lin Zhu
Lin-Lin Zhu
KHKai Huang
Kai Huang
ZHZuoying Hu
Zuoying Hu
Background: Atrial fibrillation (AF) is the most frequent tachyarrhythmia in patients with a permanent pacemaker. Angiotensin II receptor antagonists have a protective effect against the occurrence of AF in patients with heart diseases. This study aimed to assess the effectiveness of olmesartan in the prevention of new-onset AF and AF burden in atrioventricular block (AVB) patients with dual-chamber (DDD) pacemaker implantation. Methods: This was a single-center, prospective, randomized, single-blind, controlled clinical study. A total of 116 AVB patients, who received DDD pacemakers implantation with the percentage of ventricular pacing (VP%) ≥40% from April 22, 2011 to December 24, 2012, were prospectively randomized to olmesartan group (20 mg per day; n = 57) or control group (n = 59). Patients were followed up using pacemaker programming, 12-lead electrocardiography in the intrinsic sinus rhythm, laboratory examinations, and transthoracic echocardiography at 24 months. Atrial high rate events (AHREs) were defined as 180 beats/min over a minimum of 5 min. AF burden was calculated by the number of hours with AHREs divided by the number of measurement hours. Results: Ten (17.5%) patients in the olmesartan group and 24 patients (40.7%) in the control group occurred new-onset AF, and the difference between two groups was statistically significant (P = 0.04). AF burden was lower in olmesartan group than that in control group (8.02 ± 3.10% vs. 13.66 ± 6.14%, P = 0.04). There were no significant differences in mean days to the first occurrence of AHREs and mean cumulative numbers of AHREs between two groups (P = 0.89 and P = 0.42, respectively). Moreover, olmesartan group had smaller values of maximal P-wave durations and P-wave dispersion (PD) after 24 months follow-up compared with the control group (109.5 ± 7.4 ms vs. 113.4 ± 7.1 ms, P = 0.00; and 40.6 ± 4.5 ms vs. 43.3 ± 4.4 ms, P = 0.02, respectively). Left ventricular end-diastolic diameter and left ventricular ejection fraction were not significantly different between two groups (both P > 0.05). Conclusion: This study suggested that 24-month of olmesartan therapy could reduce new-onset AF and AF burden in patients with DDD pacemakers. Clinical Trial Registration: ChiCTR-TRC-12004443; http://www.chictrdb.org.

1 October 2014 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
HZHang Zhang
Hang Zhang
ZDZhenlin Dai
Zhenlin Dai
PXPinxi Xiao
Pinxi Xiao
CPChang Pan
Chang Pan
JZJuan Zhang
Juan Zhang
SCShao-Liang Chen
Shao-Liang Chen